ArticleWorld journal of clinical pediatrics2025
Juvenile arthritis damage index predicts poor response to biological treatment: A prospective cohort study.
Article in World journal of clinical pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessing joint damage in juvenile idiopathic arthritis: Guide for prescribing physical exercise with the juvenile arthritis damage index.World journal of clinical pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJuvenile arthritis damage index (JADI) is a tool that measures the degree of aggressiveness of the juvenile idiopathic arthritis (JIA) course and assesses articular [JADI - articular damage (JADI-A)] and extraarticular [JADI - extraarticular damage (JADI-E)] damage. While aggressive JIA often requires early biologic disease-modified antirheumatic drugs (bDMARDs), the utility of JADI as a predictor of treatment response remains underexplored.
aimTo evaluate the potential of JADI as a predictor of bDMARD treatment response in JIA patients.
methodsThis prospective study included 112 highly active non-systemic JIA biologic-naïve patients with a mean age of 12.2 ± 4.6 years and a median disease duration of 2.5 (interquartile range: 1-5) years. Their clinical and radiological assessment, juvenile arthritis disease activity score 71, JADI-A, and JADI-E, were evaluated twice: Before the biologic initiation (baseline) and 12 months after (end of study). At baseline, 50% had any damage, with 43% with articular damage and 23% with extraarticular damage.
resultsDuring the study, JADI-A/JADI-E improved (33.9%/9.8%), worsened (8.9%/5.4%), or remained unchanged (57.1%/84.8%). Patients with baseline damage had higher markers of JIA activity: Polyarticular course, earlier onset age, ANA-positivity, and more active joints. Patients without initial structural damage (JADI"-") were more likely (odds ratio = 3.8, 95% confidence interval: 1.6-9.0,
conclusionBaseline structural damage in JIA is associated with diminished bDMARDs efficacy, increased disability, and shorter remission duration. JADI enhances conventional clinical risk stratification by facilitating timely initiation of bDMARDs, adherence to treat-to-target strategy and tailored patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.